leisure time -WSS

leisure time

author：leisure time 2025-10-01 16:38:22 - browse：62252

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Violet CEO on training clinicians to promote more inclusive care

leisure time

explore

WSS

Why are Kaiser Permanente staff considering a strike?

FDA panel to weigh approval of NurOwn, controversial ALS drug

Drug for rare kidney disease narrowly misses mark in clinical trial

Three trends to watch in biotech in 2024

STAT Virtual Event: Putting AI to the Test

CDC's new outbreak response network to include Northeastern

hotspot

leisure time

Wikipedia

Psychedelics group wrestles with new pharma identity

Senators: Long

Hepatitis C has a cure — but many Americans still lack access to it

Medicare drug price negotiation hasn't dried up venture capital

Malaria cases in Florida and Texas: Here’s what you need to know

How Vertex's cystic fibrosis drug is changing patients' lives

The high cost of giving birth even with insurance

Second xenotransplant done with gene

In age of alternative facts, a scholarly course on calling out crap

STAT Virtual Event: Putting AI to the Test

focus

CDC's new outbreak response network to include Northeastern

Intarcia’s device

Lasker Awards 2023: Winners in biomedical research

Medical student insurance fails on mental health care coverage

Medicare drug price negotiation hasn't dried up venture capital

Medicare drug price negotiation hasn't dried up venture capital

knowledge

leisure time

explore

hotspot